XOMA Royalty (XOMA) Interest Expenses (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Interest Expenses came in at $3.4 million in Q1 2026, down 3.12% year-on-year from $3.5 million in Q1 2025, and up 10.97% quarter-over-quarter from $3.0 million in Q4 2025.
XOMA Royalty (XOMA) Interest Expenses (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Interest Expenses across 14 years of filings, most recently posting $3.4 million for Q1 2026.
- Interest Expenses for Q1 2026 came in at $3.4 million, down 3.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.9 million (down 6.06% YoY), and the FY2025 annual result was $13.0 million, down 5.85% from the prior year.
- Interest Expenses came in at $3.4 million for Q1 2026 at XOMA Royalty, up from $3.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $3.6 million in Q1 2024 to a low of $3.0 million in Q4 2025.
- The 3-year median for Interest Expenses is $3.4 million (2024), against an average of $3.4 million.
- Peak annual rise in Interest Expenses reached 2.37% in 2025, while the deepest fall reached 10.81% in 2025.
- XOMA Royalty's Interest Expenses stood at $3.4 million in 2024, then fell by 10.81% to $3.0 million in 2025, then climbed by 10.97% to $3.4 million in 2026.
- The last three Interest Expenses figures came in at $3.4 million (Q1 2026), $3.0 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 61,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -332,000.00 |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -5.58 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 3.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.36 Mn |
| Mar 31, 2026 | 3.36 Mn |
| Dec 31, 2025 | 3.03 Mn |
| Dec 31, 2025 | 3.03 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Jun 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 3.24 Mn |
| Mar 31, 2025 | 3.47 Mn |
| Mar 31, 2025 | 3.47 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Sep 30, 2024 | 3.49 Mn |
| Sep 30, 2024 | 3.49 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 3.55 Mn |
| Mar 31, 2024 | 3.55 Mn |
| Jun 30, 2021 | 172,000.00 |
| Jun 30, 2021 | 172,000.00 |